Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BBIONET Corp. 〉Preeclampsia Risk Screening

Preeclampsia Risk Screening


Preeclampsia Risk Screening


Preeclampsia (PE) is an important cause of maternal and perinatal mortality and morbidity. Consequently, a major challenge in modern obstetrics is early identification of pregnancies at high-risk of preterm PE and undertaking of the necessary measures to improve placentation and reduce the prevalence of the disease.
 
There is now evidence that a combination of maternal demographic characteristics, including medical and obstetric history, uterine artery pulsatility index (PI), mean arterial pressure (MAP) and maternal serum pregnancy associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) at 11-13 weeks' gestation can identify a high proportion of pregnancies at high-risk for PE. Such early identification of the high-risk group for PE is important because the risk may be substantially reduced by the prophylactic use of low-dose aspirin starting from 11-13 weeks.
People who like this also like
  • OEM/ODM /CRO/CMO Services
  • Regulatory Affairs Service
  • Contract Development and Manufacturing Organization (CDMO)
  • CMC / CDMO (Contract Development and Manufacturing Organization)
  • SNP Array for Prenatal Test (Genetic Testing)
  • NGS-based PGS (Genetic Testing)
  • SNP Array for POC Test (Genetic Testing)
  • One stop OEM/ODM Service for health supplement
  • Pilot scale up development and cGMP manufacturing of biopharamaceutical drug substance (DS)
  • Analytical Capability and Protein Characterization